Asterias Biotherapeutics to launch stem cell therapy trial
Almost three years after a Bay Area company shut down the world's first clinical trial of a therapy using embryonic stem cells, another local company is reviving the therapy.
Wednesday Aug 27
Stem cell trial for spinal cord injuries cleared by FDA
Michael West founded Geron, which halted its early-stage stem cell trial in spinal cord injury patients.
Geron's Neutral Rating Reaffirmed at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a research report issued on Tuesday.
Asterias Biotherapeutics Appoints Two Independent Directors and...
With these additions, the Asterias Board of Directors now comprises eight directors, three of whom are independent.
Geron's (GERN) CEO John Scarlett on Q2 2014 Results - Earnings Call Transcript
Good day ladies and gentlemen, and welcome to the Second Quarter 2014 Geron Earnings Conference Call.
Geron Corporation Reports Second Quarter 2014 Financial Results
The increase in research and development expenses for the 2014 second quarter, compared to the same period in 2013, was primarily the net result of higher costs for the manufacturing of imetelstat, partially offset by reduced personnel-related and other research costs resulting from previous restructurings and the discontinuation of the discovery ... (more)
Geron (GERN) Set to Announce Earnings on Monday
Geron is scheduled to be posting its Q214 quarterly earnings results on Monday, August 11th.
Geron Corporation To Assume Sponsorship Of Myelofibrosis IST And IND
Geron does not intend to enroll additional patients in this study. The company plans to use the transferred data and information from the Myelofibrosis IST to inform the design of Geron's planned Phase 2 clinical trial in MF.